Tag
Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased onc
A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.
This article explores the unique epidemiological landscape of anal canal cancer in Japan, highlighting the predominance of adenocarcinoma over squamous cell carcinoma and the rising role of chemoradiotherapy in clinical management.
The phase III PACIFIC-2 trial found that giving durvalumab from the start of definitive concurrent chemoradiotherapy failed to improve progression-free or overall survival versus placebo; consolidation durvalumab after chemoradiotherapy rem
The PREOPANC-2 trial compared neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer, finding no significant overall survival difference between the two regimens.
The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tum
This phase II study shows that adding metformin to standard chemoradiotherapy in locally advanced cervical cancer is safe, well tolerated, and feasible, with no significant increase in severe adverse events and successful biomarker-based tu
This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting dis
The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.
The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cel
A phase II trial reveals that high-dose twice-daily thoracic radiotherapy (60 Gy/40 fractions) significantly improves survival without increasing severe toxicity compared to the standard dose (45 Gy/30 fractions) in limited-stage SCLC patie
The ACCORD trial demonstrates that combining camrelizumab with chemoradiotherapy significantly improves survival outcomes in resectable extrahepatic cholangiocarcinoma and gallbladder cancer, with an acceptable safety profile.
A multicenter phase 3 trial demonstrates that sequential chemoradiotherapy is noninferior to induction plus concurrent chemoradiotherapy for stage III/IVA nasopharyngeal carcinoma with fewer acute toxicities.
A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting
The CHINOREC phase 2 trial demonstrates that adding ipilimumab and nivolumab to standard neoadjuvant chemoradiotherapy in rectal cancer is safe and feasible, showing promising clinical activity but no significant improvement in complete res
